Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update

被引:261
作者
Hemeryck, A [1 ]
Belpaire, FM [1 ]
机构
[1] State Univ Ghent, Heymans Inst Pharmacol, Fac Med & Hlth Sci, B-9000 Ghent, Belgium
关键词
D O I
10.2174/1389200023338017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The selective serotonin reuptake inhibitors (SSRIs) have become the most prescribed antidepressants in many countries. Although the SSRIs share a common mechanism of action, they differ substantially in their chemical structure, metabolism, and pharmacokinetics. Perhaps the most important difference between the SSRIs is their potential to cause drug-drug interactions through inhibition of cytochrome-P450 (CYP) isoforms. This paper provides an update on both the in vitro and in vivo evidence with respect to CYP-mediated drug-drug interactions with this class of antidepressants. The available evidence clearly indicates that the individual SSRIs display a distinct profile of cytochrome P450 inhibition. Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor. Fluoxetine and paroxetine are potent CYP2D6 inhibitors, whereas fluoxetine's main metabolite, norfluoxetine, has a moderate inhibitory effect on CYP3A4. Sertraline is a moderate CYP2D6 inhibitor; citalopram appears to have little effect on the major CYP isoforms. Fluoxetine :deserves special attention as inhibitory effects on CYP-activity can persist for several weeks after fluoxetine discontinuation because of the long half-life of fluoxetine and its metabolite norfluoxetine. Drug combinations with SSRIs should be assessed on an individual basis. Knowledge regarding the CYP-isoforms involved in the metabolism of the co-administered drug may help clinicians to anticipate and avoid potentially dangerous drug-drug interactions. Anticipated interactions can usually be managed by appropriate dose adjustment and titration of the object drug. In some cases, therapeutic drug monitoring can be useful. Equally well, an SSRI with limited interaction potential may be selected to treat depression in patients that receive other medications.
引用
收藏
页码:13 / 37
页数:25
相关论文
共 191 条
[41]   Comparison of (S)-mephenytoin and proguanil oxidation in vitro:: contribution of several CYP isoforms [J].
Coller, JK ;
Somogyi, AA ;
Bochner, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (02) :158-167
[42]   THE EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON CYTOCHROME-P4502D6 (CYP2D6) ACTIVITY IN HUMAN LIVER-MICROSOMES [J].
CREWE, HK ;
LENNARD, MS ;
TUCKER, GT ;
WOODS, FR ;
HADDOCK, RE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) :262-265
[43]   Effect of fluvoxamine on the pharmacokinetics of quinidine [J].
Damkier, P ;
Hansen, LL ;
Brosen, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (06) :451-456
[44]   PAROXETINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN DEPRESSIVE-ILLNESS [J].
DECHANT, KL ;
CLISSOLD, SP .
DRUGS, 1991, 41 (02) :225-253
[45]   BIOLOGICAL DISSECTION OF ANXIETY DISORDERS - THE CLINICAL ROLE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS WITH PARTICULAR REFERENCE TO FLUVOXAMINE [J].
DENBOER, JA ;
WESTENBERG, HGM ;
DELEEUW, AS ;
VANVLIET, IM .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 9 :47-52
[46]  
DEVANE CL, 1999, METABOLIC DRUG INTER, P247
[47]   Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome" [J].
Dingemanse, J ;
Wallnöfer, A ;
Gieschke, R ;
Guentert, T ;
Amrein, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (04) :403-413
[48]   Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine [J].
Dominguez, RA ;
Kumar, AM ;
Cua, W .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (04) :320-323
[49]   Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone [J].
Eap, CB ;
Bertschy, G ;
Powell, K ;
Baumann, P .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (02) :113-117
[50]   Systematic review and guide to selection of selective serotonin reuptake inhibitors [J].
Edwards, JG ;
Anderson, I .
DRUGS, 1999, 57 (04) :507-533